Roman M Chabanon

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/199396/publications.pdf

Version: 2024-02-01

1163117 1199594 11 783 8 citations h-index papers

g-index 12 12 12 1418 docs citations times ranked citing authors all docs

12

#	Article	IF	CITATIONS
1	A Novel Synthetic Lethal Approach to Target <i>MYC</i> -Driven Cancers. Cancer Research, 2022, 82, 969-971.	0.9	3
2	BCG therapy downregulates HLA-I on malignant cells to subvert antitumor immune responses in bladder cancer. Journal of Clinical Investigation, 2022, 132, .	8.2	11
3	PBRM1 Deficiency Confers Synthetic Lethality to DNA Repair Inhibitors in Cancer. Cancer Research, 2021, 81, 2888-2902.	0.9	66
4	Targeting the DNA damage response in immuno-oncology: developments and opportunities. Nature Reviews Cancer, 2021, 21, 701-717.	28.4	150
5	Exploiting epigenetic vulnerabilities in solid tumors: Novel therapeutic opportunities in the treatment of SWI/SNF-defective cancers. Seminars in Cancer Biology, 2020, 61, 180-198.	9.6	28
6	Understanding genetic determinants of resistance to immune checkpoint blockers. Seminars in Cancer Biology, 2020, 65, 123-139.	9.6	9
7	Beyond DNA repair: the novel immunological potential of PARP inhibitors. Molecular and Cellular Oncology, 2019, 6, 1-4.	0.7	18
8	PARP inhibition enhances tumor cell–intrinsic immunity in ERCC1-deficient non–small cell lung cancer. Journal of Clinical Investigation, 2019, 129, 1211-1228.	8.2	222
9	Enduring epigenetic landmarks define the cancer microenvironment. Genome Research, 2018, 28, 625-638.	5 . 5	74
10	DNA repair deficiency sensitizes lung cancer cells to NAD+ biosynthesis blockade. Journal of Clinical Investigation, 2018, 128, 1671-1687.	8.2	19
11	Mutational Landscape and Sensitivity to Immune Checkpoint Blockers. Clinical Cancer Research, 2016, 22, 4309-4321.	7.0	182